Hodgkin's Disease The type of treatment recommended depends on the clinical stage of the disease. Most therapists use some such schemne as the following:
Stage 1: A single area only involved; no constitutional signs or symptoms. In this stage radiotherapy is often used; chemotherapy is also effective with one of the milder oral mustards such as chlorambucil. After an initial course of 10 mg daily for six weeks, a maintenance dose of 2 mg daily can be given until the gland swellings have disappeared; treatment should then be stopped and not resumed unless signs of recurrence appear.
Stage 2: Involvement of two or more lymphatic areas in a single anatomical region. Subdivided into 2a without, and 2b with, constitutional signs and symptoms. In 2a radiotherapy is also used; chemotherapy should begin with a course of intravenous mustard or one of the more active oral drugs such as uracil mustard. When such a drug is used, maintenance treatment should not be given until it is clear that the original course of treatment is no longer causing depression of white cells and platelets; this may mean waiting one to three weeks. In 2b radiotherapy is not often used except for reduction of, say, a large mass of glands in the neck that is not responding to chemotherapy; the treatment is chemotherapy alone or combined with local radiotherapy. Initial intravenous therapy with trimustine is best; maintenance after the usual waiting period is best with uracil mustard.
Stage 3: Several areas involved with constitutional signs. In this stage chemotherapy is best, and since the patient may be anmmic an initial blood transfusion may be needed. A course of intravenous mustard is given, even when the initial white cell count is low, and may be repeated after an interval of one to three weeks. Oral mustards are insufficiently active for this stage. Steroids can be helpful here combined with the mustard treatment, especially if gland masses are large and if anemia or hemorrhage from thrombocytopenia is troublesome; doses of prednisolone 50 mg daily at first are needed, reducing after two or three weeks to 15 mg daily.
The other reticuloses can be similarly treated according to the clinical severity of the disease.
Brill-Symmers Reticulosis Gland masses in the neck without constitutional signs are common; they will respond well to the milder oral mustards like chlorambucil, or a quicker result can be obtained with uracil mustard; only really big masses need intravenous therapy initially. Maintenance is not used since, once the gland masses have regressed, it may be many months, even years, before enlargement recurs.
Lymphoid Reticulosis
The early stages can be adequately treated with an oral mustard drug, reserving intravenous mustard for patients with very large masses. Again maintenance is nort recommended until the inevitable recurrence appears; in some patients the recurrence comes after a short time, and then maintenance with small doses of chlorambucil or uracil mustard can be given over long periods. In the later stages mustard alone may not shrink the glands, and then prednisolone in moderate doses of 20 mg daily combined with intravenous mustard is often effective. This reticulosis is very liable to end in a leukaemic stage; when this happens prednisolone in large doses, 75-100 mg daily, is needed with cautious mustard treatment if the white cell count rises above 30,000 per c.mm.
Reticulum-cell Reticulosis
Initial treatment should always be with intravenous trimustine since the disease is always generalized. The initial course may have to be repeated after three or four weeks. If there is further recurrence after a short interval, treatment with uracil mustard or thioTEPA can be used. Combined treatment with steroids is often needed in this disease since anemia is a common complication and can be haemolytic in type; when such a himolytic anemia appears, large doses of prednisolone, 100 mg daily or more, may be needed to obtain control. The leukemias fall simply into two main groupsthe chronic leukemias and the acute leukenmias. These two groups are entirely distinct from each other in aetiology, symptomatology and particularly in their treatments -for the treatments suitable for the chronic leukemias are usually valueless or contraindicated for the acute leukemias, and vice versa (Gardikas et al. 1955 .
The acute leukmmias usually have a much shorter and more fulminating period of develop-ment and prognosis than the chronic leukaemias and consequently the need for treatment may be so much the more urgent.
Chronic Leukwmias
The chronic leuklmias comprise mainly the chronic myeloid and the chronic lymphatic types, although others such as the chronic monocytic type may be noted on rare occasions.
The fact that chronic leukimia has been diagnosed in a patient does not of necessity mean that treatment is required. It is quite common to see patients in middle or later life with low-grade chronic, usually lymphatic, leukiemia who are in quite good physical condition, while the spleen and the lymphatic glands may be only slightly enlarged with a moderate leucocytosis up to, say, 30,000-50,000; untreated, the condition may remain static for years or even for life and so antileukeemic treatment can and should be delayed until there are definite indications for treatment, e.g. increasing size of glands, spleen, rising white cell count, or a deteriorating general condition.
In the course of the last thirty years I have seen some 20 such patients, as for example the following: During the subsequent twenty years, I saw him regularly at monthly or three-monthly intervals. W.B.C. varied between 4,000 and 65,000, R.B.C. between 5,300,000 and 3,650,000, Hb between 62% (9-24 g) and 109% (16-19 g). His physical condition hardly varied, and the spleen was frequently, not always, just palpable, while he followed an extremely busy, arduous and successful professional practice. During that time he had a prostatectomy, a severe deep abscess in the leg, pleurisy, lobar pneumonia twice and cystitis. He ultimately died at the age of 78 years one year after removal of a pyloric carcinoma; his last blood count was R.B.C. 3,650,000, Hb 78% (11-4 g), W.B.C. 25,000 (polys. 6 0 %, lymphos. 92 0 %, monos. 2-0 Y.), platelets 140,000. He never required specific treatment for the leukimia.
The treatment of the chronic leukaemias in general is relatively easy if started at an early stage.
It is now some twenty-two years since I first introduced (see Wilkinson &Fletcher 1947) , during the war, the use of the chloralkylamines, now called nitrogen mustards, for the treatment of chronic myeloid and lymphatic leukeemias, Hodgkin's disease and reticuloses. Several of the patients then treated were alive until quite recently.
I first used the tri-(2-chlorethyl)amine hydrochloride, and the methyl-di-(2-chlorethyl)amine hydrochloride, and was much more impressed with the former which was a cleaner, nicer and a finely crystalline substance, easily soluble in water but rapidly hydrolysed therein: it is easy to control and has an extremely rapid and effective action in reducing enlarged spleens, livers, glands and increased leucocyte counts and showing in many cases subsequent prolonged clinical effects.
A particular feature was that these substances wereuniversallyeffectiveinthetreatmentofchronic myeloid and chronic lymphatic leukaemias as well as the reticuloses-apotential not demonstrated by any other of the many later preparations tried and used in these conditions -with one recent exception (Wilkinson 1953 , 1955 , Gardikas et al. 1955 .
Excellent results can be obtained with, for example, tri-(2-chlorethyl)amine hydrochloride in doses of 5-6 mg given in two or three doses intravenously. Nevertheless, since a proportion of these patients tended to have a certain amount of gastro-intestinal side-effects such as nausea, vomiting, loss of appetite, &c., extensive searches have been made to find preparations with fewer side-effects and which could be given orally.
Many preparations have been tried but all have had specific rather than universal applications. Thus chronic myeloid leukeemia responds in varying degree to urethane, demecolcine, mannomustine, busulphan, among many others, but chronic lymphatic leuk&emia does not and may be made worse by such preparations although it responds for example to chlorambucil, which has no beneficial effects on chronic myeloid leukiemia.
Most of these various forms of treatment have now been superseded by the few more useful agents. Thus, apart from the intravenously administered chloroethylamine (nitrogen mustard) preparations already discussed, which are still the most effective and rapidly acting of all and are used extensively, we need consider only a few of the other satisfactory agents.
In chronic myeloid leukimia the oral treatment with busulphan, originally tried by Galton & Till (1955) and by others has been and is a very simple and easy method of control but in spite of this it is still not the perfect form of treatment. Nevertheless, many patients do very well on this substance in doses of 2-4 mg daily, finally stabilizing on perhaps 2 mg weekly or less.
In my experience good control is best secured subsequently by a small maintenance dose (2 mg) weekly rather than intermittent courses with untreated intervals between, which tends to produce a spiky curve of the leucocyte levels. There are quite a number of long-term series of patients recorded now having had treatment with busulphan (Wilkinson & Turner 1959 . It is the only substance I know of that can be given orally with extreme safety, with few slight side-effects, and has almost the same clinical and effective, but slightly slower, action that is obtained when tri-(2-chlorethyl)-amine hydrochloride is given intravenously to patients with chronic myeloid and chronic lymphatic leukeemias, Hodgkin's disease, and reticuloses among other conditions.
The initial dosage employed is 3-5 mg orally per day in single or divided doses after meals, and in the course of the subsequent one to two weeks the dose can be reduced to 1-3 mg daily according to the'clinical and himatological responses. It can be given as outpatient therapy, which I usually do, and can be continued indefinitely in the small maintenance doses ultimately of perhaps 1 mg weekly or fortnightly.
Of 92 patients treated for the above different diseases 7 complained of slight nausea, vomiting or looseness of the bowels but only after being given 5 mg daily for some days; these symptoms all cleared immediately on reducing the dosage to less than 3 mg daily or after temporarily stopping it for a few days.
Chronic myeloid leukeemia: Twenty-one patients (aged 19 to 72 years; males 14, females 7) with chronic. myeloid leukaemia were given uracil mustard orally; 3 of them had been treated previously with busulphan or intravenous trimustine.
The -uracil mustard was given in a dosage of 3-5 mg daily initially, and then the dose was adjusted according to the blood count and clinical response to 1 mg once or twice weekly.
The spleens were considerably enlarged in all 21 patients, but following treatment with uracil mustard they were greatly reduced in size in 19 of them, 5 becoming impalpable, and only 2 remained unchanged.
The livers were enlarged-in 17 but returned to normal 'size after treatment in all except on'e patient. Nine patients had enlarged lymph glands and in all cases they became impalpable. The peripheral white cell count was considerably raised in all when treatment was begun, 11 were between 200,000 and 501,000, 8 between 100,000 and 200,000 and only 2 had white cell counts below 100,000. The white cell counts were reduced in all to the desired levels of 15,000L20,000. In 19 of the 21 patients the white cell count was reduced to half within two weeks of receiving the uracil mustard and eventually to less than 20,000 per c.mm. Of the 3 patients whose platelet counts were less than 100,000 when first'seen, 2 died within twelve' weeks and the third showed an increase in the platelet count on treatment. Five patients showed falls in the platelet counts to 20,000 per c.mm. and within four months two died from cerebellar hemorrhages, and I with a subdural hmmatoma. Nine of the 21 patients were still alive eighteen months after commencingthis treatment, 5 have survived on uracil mustard some three years and 2 for four years, the total period of observations so far.
Chronic lymphatic leukamia: As mentioned above, intravenously-given tri-(2-chlorethyl)amine hydrochloride is also a rapid and effective treatment for chronic lymphatic leukaemia and will reduce enlarged glands, spleen and a high leucocyte count within one to two weeks. An alternative oral method of treatment is, of course, with chlorambucil in doses of 5-10 mg daily for as long as the clinical and hematological conditions require. It is a relatively mild form of therapy with little in the way of side-effects; but care has to be taken to avoid overdosage and subsequent leucopenia and thrombocytopenia in an endeavour to treat severe cases of lymphatic leukemia which do not readily respond to this agent.
While uracil mustard has already been shown to be very efficient in the treatment of chronic myeloid leukemia, it has proved equally effective in dealing with chronic lymphatic leukemia and is given in a similar dosage schedule. The regression of the enlarged glands provides an excellent and obvious measure for controlling the required amount of treatment.
Of the 18 patients (11 males, 7 females; aged 47 to 81 years) treated with uracil mustard, most had had symptoms for up to two years prior to treatment and 3 of them had previously been treated with one or more of chlorambucil, prednisolone, thioTEPA, TEM, mannomustine, nitrogen mustards, and X-ray therapy.
Uracil mustard was given orally to these patients in doses as already discussed. Of these, 16 had much enlarged peripheral glands which after uracil mustard diminished considerably in size in 13 patients; 8 out of 14 patients with enlarged spleens showed considerable reduction in size, while 5 out of 11 with enlarged livers also had marked reduction in size after treatment.
The initial white cell counts were elevated in all the patients except one who had had much previous therapy: 7 had white cell counts of 50,000-100,000, and 10 had counts of 200,000-500,000. The white cell counts were reduced in all these 17 patients and while 14 showed reduction to half within two weeks, in 13 they fell to <20,000 eventually. The platelet counts fell to < 20,000 in 7 patients at some time during the course of treatment but in only 2 of these was any bruising observed. Six of these patients are still alive and well after nearly threeyears (Wilkinson etal. 1963 ).
Acute Leukemias None of the preparations normally used for the treatment, of the chronic leukxmias has any-value in the treatment of the acute leukwmias, except in those rarer cases where the leucocyte count is or goes very high and only then can they be corrected by one dose of nitrogen mustard intravenously or by uracil mustard orally for a few days.
Otherwise, a wide variety of other types of cytotoxic substances have been tried -the socalled anti-metabolites, such as folic acid antagonists, glutamine antagonists, purine antagonists (6-mercaptopurine); pyrimidine antagonists (6-azauridine); adrenal cortical steroids, and a miscellaneous group of unrelated substances. In the main these are all cytotoxic substances that can and do readily produce, if not carefully controlled, toxic side-effects which may sometimes be confused by the inexperienced with the normal symptoms of deteriorating acute leukaemia.
In general, and despite the enthusiastic claims that have so frequently been made, the ultimate prognosis of nearly all acute leukemias seems to be about the same whatever treatment or combination of treatments is given -as becomes clear when long-term trials are carried out.
Perhaps the best form of therapy -certainly in our experience -has been associated with the intelligent and bold use of steroids such as prednisolone or prednisone in doses up to 75 mg daily. We have not experienced any better results using other steroids or combining with other agents.
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As others have found, a proportion of patientsusually children with acute lymphatic leukaemiamay show prolonged remissions lasting over several or more years. Thus my best case was:
Case 2 G A, female, aged 5 First seen by me in 1951 when she had been referred from another hospital with a diagnosis, confirmed by us, of acute lymphatic leukaemia. R.B.C. 1,720,000, Hb 39 % (5 7 g), W.B.C. 4,650 (polys. 8-5 %, lymphos. 88-5%, monos. 15%, eosinos. 0 5%), platelets 31,000. She was treated with steroids 25-50 mg daily, intramuscularly, then orally, for ten weeks, with two supporting blood transfusions, followed by a second course of steroids in reducing amounts, orally, over a total period of five months. The treatment was discontinued on 19.8.52 when her blood count was normal.
Since then, I have seen her every three months and she has remained quite well, with normal blood counts, and no evidence of any blood dyscrasia. She is now 17 years old and has led a normal and full life for the last eleven years.
Present blood count: R.B.C. 4,660,000, Hb 93% (13-6 g), W.B.C. 8,100 (normal differential count). (25) , lymphatic (7) and primitive cell (7) leukemias, and immature cell erythremias (6 4), the least being the acute monocytic (2), reticulum cell (4) and myeloblastic (4) leukTEmias.
In this series, at the time of writing, we still have 10 patients alive: 7 (6 adults) after six to twelve months, 2 (1 adult) twelve to twenty-eight months, and one nearly twelve years.
Uracil mustard may be only of temporary value in the treatment of patients with acute leukxemia when the leucocyte count is considerably increased; thus 4 such patients, with leucocyte counts of 55,000-176,000, showed rapid reduction in these to normal levels without any clinical improvement on 1-3 mg orally daily for one week.
6-Azauridine: In the sequence of events leading to the de novo biosynthesis of pyrimidine nucleotides, azauridylic acid can interrupt the major pathway by acting as a competitive inhibitor of the enzyme orotodylic decarboxylase, which normally decarboxylates the orotodylic acid to uridylic acid.
The most convenient way of taking advantage of this is to use 6-azauridine which is rapidly converted in the body to azauridylic acid under the influences of uridine kinase.
6-azauridine is a potent inhibitor of animal tumours and has some effect on human tumours. It has therefore been tried out on patients with acute leukemia. 6-azauridine is extremely difficult to prepare in a pure form, which is essential, and so far has only been available in quantities sufficient to try it out on some 15 cases -13 having acute leukwemia.
The dosage used has been 10-20 g daily for periods of twenty-one days given as a continuous intravenous dripthroughoutthetwenty-fourhours. Pure 6-azauridine is remarkably free from toxic effects of any kinds, but produces a very rapid fall in the total white cell count showing a preferential effect on blast cells.
It has produced dramatic effects in resolving leukxemic infiltration of the skin, reducing enlarged lymph nodes and spleen, and in most patients it hasproduced rapid subjective improvement.
Since it is a potent inhibitor of nucleic acid synthesis, gross chromosomal changes may be produced (Elves et al. 1963) .
The inconvenience of continuous intravenous therapy can be obviated by the use of the triacetyl derivative which works in the same manner when given in doses of 7 5-10 g orally.
The most striking results are the preferential effects on the blast cells which were diminished dramatically in all the 13 acute leukemias .
